Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Some of our 2023 plans
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Hypertension
    • Patents and intellectual property
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Some of our 2023 plans
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Hypertension
    • Patents and intellectual property
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!
Get involved
Our campaigns
Echis ocellatus is a venomous viper species endemic to West Africa.
Issue brief |
24 January 2018

142nd WHO EB Agenda item 4.1 - Global snakebite burden

TROPICAL & NEGLECTED DISEASES
May.2018_71st WHO-WHA Global snakebite burden
Photograph by Gabriel Martinez

Global Snakebite Burden - WHO Executive Board, 142nd Session, January 2018

Provisional agenda item 4.1 (EB142/17)
Navigate
  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access Campaign
Médecins Sans Frontières
Route de Ferney 140 
P.O. Box 1224
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us
  • Twitter
  • Facebook
  • Vimeo
  • Medium
Medicines Shouldn't Be A Luxury